- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: Fluticasone Furoate/Vilanterol (FF/VI)
Total 1619 results
-
AstraZenecaCompletedPeripheral Arterial Disease (PAD) | Moderate Risk for Cardiovascular Disease (CVD)France, Netherlands, Switzerland, Greece, Belgium, Italy
-
Hoffmann-La RocheRecruitingMultiple Sclerosis, Primary ProgressiveCanada, United States, Spain, Croatia, Serbia, Portugal, France, Tunisia, Mexico, Poland, Russian Federation, Australia, Belgium, Italy, United Kingdom, Ukraine, Bulgaria, Colombia, Georgia, Germany, Romania, New Zealand, Lebanon, Aus... and more
-
Hoffmann-La RocheActive, not recruitingEsophageal Squamous Cell CarcinomaUnited States, France, Spain, Australia, Korea, Republic of, Argentina, Belgium, China, Portugal, Taiwan, Japan, Germany, Poland, Thailand, United Kingdom, Switzerland, Turkey, Russian Federation, Morocco, Greece, Italy, New Zealand, South Africa and more
-
PfizerInternational Collaborative Cancer GroupCompletedBreast NeoplasmsAustralia, Denmark, Netherlands, United States, Bulgaria, Hungary, Italy, Spain, Belgium, Czech Republic, Ireland, Poland, Russian Federation, Sweden, United Kingdom, Croatia, Serbia, Germany, Bosnia and Herzegovina, Norway, South... and more
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary DiseaseGermany, United States, Colombia, Poland, South Africa, Canada, Estonia, Hungary, India, Austria, Israel, Netherlands, United Kingdom, Argentina, France, Italy, Spain, Czech Republic, Denmark, Finland, Greece, Ireland, Mexico, Peru, Phi... and more
-
Novartis PharmaceuticalsTerminatedAcute Heart Failure (AHF)Germany, Belgium, Croatia, Estonia, Hungary, Lithuania, Russian Federation, Austria, Switzerland, Spain, France, Greece, Slovenia, Bulgaria, Czechia, Italy, Serbia, Finland, United Kingdom, Poland, Portugal, Romania, Latvia, Slovakia, I...
-
Genentech, Inc.Roche Pharma AGTerminatedRheumatoid ArthritisUnited States, Belgium, Canada, Hungary, Argentina, Germany, Spain, Brazil, Poland, Israel, Mexico, Japan, France, Peru, Switzerland, Sweden, Italy, Australia, New Zealand, Panama, Czechia, Netherlands, Slovakia, Slovenia, Taiwan
-
PfizerCompletedCarcinoma, Non-Small-Cell LungUnited States, Canada, Spain, China, Brazil, United Kingdom, Japan, Poland, Australia, France, Ireland, Taiwan, Italy, Germany, Netherlands, Korea, Republic of, Bulgaria, Greece, Hong Kong, Hungary, Russian Federation, Sweden
-
La Jolla Pharmaceutical CompanyTerminatedLupus Erythematosus, Systemic | Lupus NephritisTaiwan, United States, Belarus, Serbia, Czech Republic, Philippines, Lebanon, India, Korea, Republic of, Argentina, Australia, Brazil, Bulgaria, Georgia, Germany, Hong Kong, Hungary, Indonesia, Italy, Malaysia, Mexico, Poland, Portugal and more
-
Lexicon PharmaceuticalsSanofiTerminatedHeart Failure | Type 2 Diabetes MellitusBelgium, Canada, Israel, Spain, Germany, Argentina, Chile, Hungary, Korea, Republic of, Latvia, Lithuania, Russian Federation, Sweden, Romania, Poland, Brazil, Denmark, United States, Australia, Austria, Czechia, Finland, France, Greece, Ita... and more
-
Merck Sharp & Dohme LLCActive, not recruitingCarcinoma, Non-Small-Cell Lung | Lung NeoplasmsPoland, Romania, Ukraine, Chile, Canada, United States, Argentina, China, Czechia, Estonia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Norway, Peru, Russian Federation, Spain, Thailand, Turkey, United...
-
PfizerCompletedCarcinoma, Non-Small-Cell LungUnited States, Canada, Spain, China, United Kingdom, Poland, France, Ireland, Japan, Taiwan, Germany, Netherlands, Italy, Brazil, Russian Federation, Korea, Republic of, Australia, Bulgaria, Greece, Hong Kong, Hungary, Sweden
-
Novartis PharmaceuticalsCompletedRelapsing Forms of Multiple SclerosisGermany, South Africa, Italy, United States, Austria, Belgium, Czechia, Egypt, Hungary, Malaysia, Turkey, Spain, Australia, Canada, France, Israel, Netherlands, Switzerland, Greece, Korea, Republic of, Romania, Russian Federation, United... and more
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsEnrolling by invitationPrimary Hyperoxaluria Type 3 | Diabetes Mellitus | Hemophilia A | Hemophilia B | Hereditary Fructose Intolerance | Cystic Fibrosis | Factor VII Deficiency | Phenylketonurias | Sickle Cell Disease | Dravet Syndrome | Duchenne Muscular Dystrophy | Prader-Willi Syndrome | Fragile X Syndrome | Chronic Granulomatous Disease and other conditionsUnited States
-
NSABP Foundation IncHoffmann-La Roche; Genentech, Inc.; Cancer International Research Group (CIRG)TerminatedBreast CancerKorea, Republic of, United States, Canada, Spain, Ireland, Australia, Argentina, China, United Kingdom, Germany, Brazil, Hong Kong, France, Israel, Taiwan, Serbia, Belgium, Thailand, Croatia, Egypt, Italy, Philippines, Bosnia and Herzegovina and more
-
Novartis PharmaceuticalsCompletedCOPDGermany, Belgium, Poland, Romania, Italy, Spain, Estonia, Russian Federation, Austria, France, Slovakia, Czechia, Latvia, Lithuania, Greece, Hungary, United Kingdom, Portugal, Ireland, Norway, Slovenia, Denmark, Sweden
-
PfizerCompletedClostridium Difficile InfectionUnited States, Spain, Belgium, Taiwan, Japan, Portugal, Colombia, Korea, Republic of, Poland, Australia, Germany, Canada, Argentina, Bulgaria, Chile, Czechia, Finland, France, Hungary, Peru, Slovakia, Sweden, United Kingdom
-
Novo Nordisk A/SRecruitingInflammation | Chronic Kidney Disease | Cardiovascular RiskKorea, Republic of, Italy, United States, Spain, China, Taiwan, Mexico, Netherlands, Latvia, Malaysia, Thailand, Hungary, Australia, Poland, South Africa, India, Canada, Portugal, Romania, United Kingdom, Bulgaria, Germany, Brazil, Sw... and more
-
Johnson & Johnson Pharmaceutical Research & Development...BayerCompletedStroke | Embolism | Atrial FibrillationUnited States, Australia, France, Poland, Ukraine, United Kingdom, China, Belgium, Germany, Taiwan, Spain, Argentina, Colombia, Israel, Mexico, Bulgaria, India, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic... and more